Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma - Summary - MDSpire

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

  • By

  • Xiuqin An

  • Yanfang Gao

  • Shangyumeng Zhao

  • Wei He

  • Xinda Yang

  • Yujie Wu

  • Jihao Li

  • Runxi Yi

  • Yue Han

  • Mingxuan Li

  • Qiusheng Li

  • Ting Yang

  • June 17, 2026

  • 0 min

Share

Objective:

To correct an error in the published figure related to the association of MAPRE2 with macrophage-enriched innate immunity and malignant characteristics in hepatocellular carcinoma.

Approach:
    Key Findings:
    • The error was limited to the representative microscopy image displayed in Figure 7A.
    • All quantitative cell-count data, statistical values, significance levels, figure legend, results, and conclusions remain unchanged.
    Interpretation:

    The authors have verified the original unprocessed microscopy files and confirmed the integrity of the data aside from the image error.

    Limitations:
    • The correction does not affect the overall findings or conclusions of the study.
    Conclusion:

    The original version of the article has been updated to reflect the corrected figure.

    Sources:

Original Source(s)

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

  • by Xiuqin An, Yanfang Gao, Shangyumeng Zhao, Wei He, Xinda Yang, Yujie Wu, Jihao Li, Runxi Yi, Yue Han, Mingxuan Li, Qiusheng Li, Ting Yang

  • June 17, 2026

Related Content

Waldenström macroglobulinemia-associated renal AL amyloidosis: a case report and literature review

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia